UPM Stock Analysis: UPM-Kymmene | HE
Paper & Paper Products | HE, Finland | Market Cap: 11.891m EUR | 12M Return: 0.8% | FI0009005987 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 25.2M
EPS Trend: -18.4%
Qual. Beats: -1
Rev. Trend: -92.0%
Qual. Beats: -2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
UPM-Kymmene Oyj is a Finnish forest-based bioindustry company operating across seven business segments, including fibres, energy, adhesive materials, specialty papers, communication papers, plywood, and other operations. Its product portfolio spans pulp, sawn timber, renewable diesel and naphtha, plywood, veneer, biomedical products such as nano-fibrillar cellulose, wood-based lignin, and biochemicals designed to replace fossil-based raw materials. The company also generates electricity through hydro, thermal, and nuclear power plants.
UPM serves a diverse customer base including publishers, printing houses, converters, label manufacturers, brand owners, industrial users, and producers of tissue, board, and graphic papers. The integrated business model covers the full value chain from forestry services and wood sourcing to finished industrial and consumer-facing products, with vertically aligned activities such as forestry water protection and financial portfolio management.
As one of Europes largest diversified forest products companies, UPM represents the broader materials and paper products sector, where players are increasingly pivoting from traditional graphic papers toward higher-value specialty papers, packaging, biofuels, and biochemicals. Founded in 1871 and headquartered in Helsinki, Finland, the company has a long heritage in the Nordic pulp and paper industry, which benefits from extensive domestic forest resources.
- UPM Fibres pulp margins track Chinese demand and global supply discipline
- Nordic electricity prices drive UPM Energy earnings volatility
- Rotterdam biofuel refinery startup reshapes long-term capital allocation
| Net Income: 688.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.18 > 1.0 |
| NWC/Revenue: 16.23% < 20% (prev 16.78%; Δ -0.55% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.36b > Net Income 688.0m |
| Net Debt (3.84b) to EBITDA (1.54b): 2.50 < 3 |
| Current Ratio: 1.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (527.3m) vs 12m ago 0.0% < -2% |
| Gross Margin: 5.29% > 18% (prev 11.65%; Δ -6.36% > 0.5%) |
| Asset Turnover: 52.13% > 50% (prev 55.28%; Δ -3.16% > 0%) |
| Interest Coverage Ratio: 10.83 > 6 (EBIT TTM 1.02b / Interest Expense TTM 94.0m) |
| A: 0.08 (Total Current Assets 4.09b - Total Current Liabilities 2.57b) / Total Assets 17.9b |
| B: 0.33 (Retained Earnings 5.88b / Total Assets 17.9b) |
| C: 0.06 (EBIT TTM 1.02b / Avg Total Assets 18.0b) |
| D: 1.36 (Book Value of Equity 10.1b / Total Liabilities 7.45b) |
| Altman-Z'' = 3.43 = A |
| DSRI: 0.86 (Receivables 1.43b/1.76b, Revenue 9.37b/9.98b) |
| GMI: 2.20 (GM 11.65% / 5.29%) |
| AQI: 1.04 (AQ_t 0.23 / AQ_t-1 0.22) |
| SGI: 0.94 (Revenue 9.37b / 9.98b) |
| TATA: -0.04 (NI 688.0m - CFO 1.36b) / TA 17.9b) |
| Beneish M = -2.07 (Cap -4..+1) = BB |
As of November 17, 2026, the stock is trading at EUR 22.36 with a total of 897,507 shares traded. Over the past week, the price has changed by +2.71%, over one month by -11.23%, over three months by +1.38% and over the past year by +0.80%.
Current recommended Stop Loss: 21.20 (which is 5.2% or 2.2 ATR below the current price).
UPM-Kymmene has no consensus analysts rating.
P/E Trailing = 17.6172
P/E Forward = 12.0919
P/S = 1.2518
P/B = 1.174
P/EG = 12.8895
Revenue TTM = 9.37b EUR
EBIT TTM = 1.02b EUR
EBITDA TTM = 1.54b EUR
Long Term Debt = 2.84b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 147.0m EUR (from shortTermDebt, last quarter)
Debt = 4.51b EUR (from shortLongTermDebtTotal, last quarter) + Leases 772.0m
Net Debt = 3.84b EUR (calculated: Debt 4.51b - CCE 663.0m)
Enterprise Value = 15.7b EUR (11.9b + Debt 4.51b - CCE 663.0m)
Interest Coverage Ratio = 10.83 (Ebit TTM 1.02b / Interest Expense TTM 94.0m)
EV/FCF = 15.64x (Enterprise Value 15.7b / FCF TTM 1.01b)
FCF Yield = 6.39% (FCF TTM 1.01b / Enterprise Value 15.7b)
FCF Margin = 10.73% (FCF TTM 1.01b / Revenue TTM 9.37b)
Net Margin = 7.34% (Net Income TTM 688.0m / Revenue TTM 9.37b)
Gross Margin = 5.29% ((Revenue TTM 9.37b - Cost of Revenue TTM 8.88b) / Revenue TTM)
Gross Margin QoQ = 3.86% (prev 11.97%)
Tobins Q-Ratio = 0.88 (Enterprise Value 15.7b / Total Assets 17.9b)
Interest Expense / Debt = 2.09% (Interest Expense 94.0m / Debt 4.51b)
Taxrate = 22.70% (205.0m / 903.0m)
NOPAT = 786.9m (EBIT 1.02b * (1 - 22.70%))
Current Ratio = 1.59 (Total Current Assets 4.09b / Total Current Liabilities 2.57b)
Debt / Equity = 0.44 (Debt 4.51b / totalStockholderEquity, last quarter 10.1b)
Debt / EBITDA = 2.50 (Net Debt 3.84b / EBITDA 1.54b)
Debt / FCF = 3.82 (Net Debt 3.84b / FCF TTM 1.01b)
Total Stockholder Equity = 10.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.83% (Net Income 688.0m / Total Assets 17.9b)
RoE = 6.82% (Net Income TTM 688.0m / Total Stockholder Equity 10.1b)
RoCE = 7.87% (EBIT 1.02b / Capital Employed (Equity 10.1b + L.T.Debt 2.84b))
RoIC = 5.24% (NOPAT 786.9m / Invested Capital 15.0b)
WACC = 5.81% (E(11.9b)/V(16.4b) * Re(7.40%) + D(4.51b)/V(16.4b) * Rd(2.09%) * (1-Tc(0.23)))
Discount Rate = 7.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -31.03 | Cagr: -0.50%
[DCF] Terminal Value 77.97% ; FCFF base≈923.6m ; Y1≈1.06b ; Y5≈1.56b
[DCF] Fair Price = 37.18 (EV 23.4b - Net Debt 3.84b = Equity 19.6b / Shares 527.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -18.43 | EPS CAGR: -1.83% | SUE: -1.26 | # QB: -1
Revenue Correlation: -91.99 | Revenue CAGR: -4.03% | SUE: -1.37 | # QB: -2
EPS current Quarter (2027-03-31): EPS=0.48 | Chg30d=+11.63% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=1.25 | Chg30d=-10.66% | Revisions=-77% | GrowthEPS=-6.0% | GrowthRev=-2.7%
EPS next Year (2027-12-31): EPS=1.68 | Chg30d=-9.21% | Revisions=-50% | GrowthEPS=+34.2% | GrowthRev=+5.0%
[Analyst] Revisions Ratio: -64% (up=3, down=19)